ionis pharmaceuticals

News

Ionis, FDA

FDA approves Ionis drug that prevents swelling attacks caused by a rare disease

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic condition, hereditary angioedema.

· 2h

FDA approves Ionis’ donidalorsen for HAE attack prevention

· 15h · on MSN

US FDA approves Ionis' drug for rare genetic disorder

BioSpace9m

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

TipRanks on MSN3h

Ionis Pharmaceuticals price target raised to $82 from $77 at Wells Fargo

Wells Fargo analyst Yanan Zhu raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $82 from $77 and keeps an Overweight rating on the ...

21h

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

TipRanks on MSN4h

Ionis Pharmaceuticals price target raised to $58 from $57 at Barclays

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $58 from $57 and keeps an Overweight rating on the shares. The firm says Dawnzera was approved by the FDA on time with a ...

Hosted on MSN20h

Ionis Pharmaceuticals trading halted, news pending

09:38 EDT Ionis Pharmaceuticals (IONS) trading halted, news pending Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results